Can Gaming Get You Fit? A High-Intensity Exergaming Intervention in Adults

December 9, 2019 updated by: Norwegian University of Science and Technology

Motivational High Intensity Training Through a Cutting-edge Gaming Platform. A Randomised, Controlled Trial

The purpose of this project is to assess if playing a newly developed videogame that require physical activity (e.g. exergame) can lead to health benefits. The project will include 50 adult participants that are not particularly physically active. They will be randomized into two groups where one group will be given free access to the exergame for 6 months. The physical fitness (maximal oxygen consumption), blood markers of cardiometabolic health and body composition of the subjects will be tested before, mid-ways and after the intervention period. Also, the participants gaming frequency will be registered throughout the 6-month period. Aim of this study is to investigate if access to this game can provide health benefits for individuals who are not motivated to take part in regular physical activity.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Norway
      • Trondheim, Norway, 7491
        • Department of Circulation and Medical Imaging

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Sedentary (<150 mins of moderate intensity physical activity/week)
  • Able to ride a bike for up to 60 minutes

Exclusion Criteria:

  • Known cardiovascular disease
  • Taking beta-blockers or anti-arrhythmic drugs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exergaming
free access to the exergame PedalTanks
Behavioral: Exergaming
free access to the exergame PedalTanks during 6 months
Other Names:
  • PlayPulse
  • PedalTanks
No Intervention: Control
recommended to continue with their normal daily routine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
VO2max (Maximal Aerobic Capacity)
Time Frame: 3 months
3 months
VO2max (Maximal Aerobic Capacity)
Time Frame: 6 months
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daily average energy expenditure
Time Frame: 3 and 6 months
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
3 and 6 months
Daily average number of steps
Time Frame: 3 and 6 months
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
3 and 6 months
Daily time in sedentary activity (< 3.0 metabolic equivalents = METs)
Time Frame: 3 and 6 months
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
3 and 6 months
Daily time in moderate intensity activity (3.0-6.0 metabolic equivalents = METs)
Time Frame: 3 and 6 months
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
3 and 6 months
Daily time in vigorous intensity activity (6.0-9.0 metabolic equivalents = METs)
Time Frame: 3 and 6 months
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
3 and 6 months
Daily time in very vigorous intensity activity (>9.0 metabolic equivalents = METs)
Time Frame: 3 and 6 months
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
3 and 6 months
Daily average total physical activity duration
Time Frame: 3 and 6 months
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
3 and 6 months
Bioelectrical impedance
Time Frame: 3 and 6 months
Body composition assessed using bioelectrical impedance analysis (InBody 720)
3 and 6 months
Blood Pressure
Time Frame: 3 and 6 months
3 and 6 months
Fasting circulating glucose, as blood marker of cardiometabolic health
Time Frame: 6 months
6 months
Lipid profile, as blood marker of cardiometabolic health
Time Frame: 6 months
6 months
Circulating insulin concentration, as blood marker of cardiometabolic health
Time Frame: 6 months
6 months
glucose response to a 2 hour glucose tolerance test, as blood marker of cardiometabolic health
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Norwegian University of Science and Technology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 25, 2018

Primary Completion (Actual)

November 30, 2019

Study Completion (Actual)

November 30, 2019

Study Registration Dates

First Submitted

April 5, 2018

First Submitted That Met QC Criteria

April 30, 2018

First Posted (Actual)

May 1, 2018

Study Record Updates

Last Update Posted (Actual)

December 11, 2019

Last Update Submitted That Met QC Criteria

December 9, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2017/1501

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe